中国癌症杂志 ›› 2013, Vol. 23 ›› Issue (6): 467-471.doi: 10.3969/j.issn.1007-3969.2013.06.012

• 综述 • 上一篇    下一篇

应用利妥昔单抗治疗弥漫性大B细胞淋巴瘤预后相关标志物的再评估

范艳兰,李小秋   

  1. 复旦大学附属肿瘤医院病理科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2013-06-25 发布日期:2014-11-13
  • 通信作者: 李小秋 E-mail:leexiaoqiu@hotmail.com

Reevaluation of predictive biomarkers of diffuse large B-cell lymphoma in the rituximab era

FAN Yan-lan, LI Xiao-qiu   

  1. Department of Pathology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 20032, China
  • Published:2013-06-25 Online:2014-11-13
  • Contact: LI Xiao-qiu E-mail: leexiaoqiu@hotmail.com

摘要:

弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)是一组在发病机制和细胞起源方面都具有异质性的肿瘤。早期的预后模型(如国际预后指数)着重强调年龄、临床分期、行为状态评分等临床因素对患者预后的影响,并未反映这类疾病生物学异质的特点。虽然曾有研究表明,某些分子标志物与该类肿瘤的预后存在明确相关性,但随着抗CD20的利妥昔单抗日益广泛的应用,DLBCL的治疗策略和疗效均发生了相应的变化。因此,在当前免疫化疗治疗模式下,有必要对DLBCL原有的预后相关分子指标予以重新评估。

关键词: 弥漫性大B细胞淋巴瘤, 预后, 标志物, 利妥昔单抗

Abstract:

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in terms of molecular pathogenesis and cell of origin. Earlier prognostic models relied mainly on such clinical variables as age, stage of disease, and performance status, which did not display its heterogeneity. Many studies have reported that some biomarkers could be used for prognostication, while older prognostic models need to be revalidated and modified as improved therapeutic options become available. In this review, we discussed pertinent studies on individual biomarkers and pattern-based biomarker models, with an emphasis on markers evaluated in patients treated with rituximabcontaining chemotherapy.

Key words: Diffuse large B-cell lymphoma, Prognosis, Biomarkers, Rituximab